KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kyverna Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$5.83+0.16 (+2.82%)
Close on Oct 19, 2026
- Market cap
- $355.03M
- P/E (TTM)
- –
- Dividend yield
- –
Kyverna Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Kyverna Therapeutics | Industry median |
|---|---|---|
| Market Cap | $360.55M | $166.30M |
| Enterprise Value | $186.03M | $88.19M |
| PB Ratio | 2.18 | 2.03 |
| P/TBV Ratio | 2.18 | 2.29 |
Income (trailing twelve months)
| Measure | Kyverna Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$158.93M | -$21.40M |
| Net Income | -$152.64M | -$22.46M |
| EBITDA | -$157.61M | -$16.91M |
| EPS (Diluted) | -$2.94 | -$0.83 |
Returns
| Measure | Kyverna Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -87.2% | -53.2% |
| Return on Assets (ROA) | -68.4% | -40.9% |
| Return on Capital Employed (ROCE) | -80.7% | -38.1% |
Balance sheet
| Measure | Kyverna Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $199.40M | $61.43M |
| Total Debt | $24.88M | $118.52M |
| Net Cash (Debt) | $174.52M | $15.35M |
| Net Cash Per Share | $2.82 | $0.66 |
| Equity (Book Value) | $165.55M | $49.09M |
| Book Value Per Share | $2.68 | $1.37 |
| Tangible Book Value | $165.55M | $23.52M |
| Working Capital | $183.74M | $76.81M |
Financial position
| Measure | Kyverna Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 9.06 | 3.34 |
| Quick Ratio | 8.74 | 2.44 |
| Debt / Equity | 0.15 | 0.52 |
| Interest Coverage | -88.69 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Kyverna Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$158.75M | -$12.35M |
Efficiency
| Measure | Kyverna Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.17M | -$703.34K |
| Employee Count | 130 | 74 |
Dividends and yields
| Measure | Kyverna Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -42.3% | -23.3% |
Shares
| Measure | Kyverna Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 61,843,400 | 58,127,000 |
| Shares Change (YoY) | 22.6% | 10.9% |
| Shares Change (QoQ) | 1.71% | 0.54% |
| Float | 55,981,700 | 49,136,700 |
| Shares Held by Insiders | 9.48% | 11.6% |
| Shares Held by Institutions | 60.8% | 59.4% |
Scores
| Measure | Kyverna Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -0.60 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Kyverna Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.